Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study

PLoS One. 2020 Aug 20;15(8):e0237739. doi: 10.1371/journal.pone.0237739. eCollection 2020.

Abstract

Objective: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients.

Methods: We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time.

Results: The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30-43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values.

Conclusions: In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage
  • Anti-Retroviral Agents / blood
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Atherosclerosis / blood*
  • Atherosclerosis / drug therapy
  • Atherosclerosis / virology
  • Biomarkers / blood*
  • C-Reactive Protein / metabolism
  • Carotid Intima-Media Thickness
  • Cholesterol / blood
  • Control Groups
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Humans
  • Inflammation / blood
  • Inflammation / drug therapy
  • Inflammation / virology
  • Lipids / blood*
  • Lipoproteins, LDL / blood
  • Male
  • Prospective Studies

Substances

  • Anti-Retroviral Agents
  • Biomarkers
  • Lipids
  • Lipoproteins, LDL
  • C-Reactive Protein
  • Cholesterol

Grants and funding

Authors who received the award: DP and MS Instituto de Salud Carlos III (PI11/02004) The funder did not play any role in the study design, data collection and analysis, decisión to publish, or preparation of the manuscript.